尿道上皮癌治療藥的全球市場

Urothelial Cancer Drugs

出版日期: 2023年04月01日 | 出版商:

Global Industry Analysts, Inc. | 英文 93 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

尿道上皮癌治療藥的全球市場在2030年前將達到153億美元

在COVID-19後改變的商務環境中，2022年24億美元的尿道上皮癌治療藥的全球市場，在2030年前將達到153億美元的規模，在2022年～2030年預計將以年複合成長率26.3％增長。本報告所分析之市場區隔之一的免疫療法年複合成長率將記錄25.7％，到分析期間結束時將達到120億美元。考慮疫情後的復甦，化療領域今後8年的年複合成長率將修正為28.6％。

美國市場估算為6億9,330萬美元，中國則將以年複合成長率25.5％的速度成長

美國的尿道上皮癌治療藥市場，2022年6億9,330萬美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為25.5％，在2030年前將達到26億美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以23％和21.9％的速度成長。在歐洲市場中，德國以年複合成長率17.6％成長。

調查對像企業範例

AstraZeneca
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Co.
Exelixis, Inc
Genentech
GlaxoSmithKline
Merck
Novartis International AG
Pfizer

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Urothelial Cancer Drugs Market to Reach $15.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Urothelial Cancer Drugs estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$15.3 Billion by 2030, growing at aCAGR of 26.3% over the period 2022-2030. Immunotherapy, one of the segments analyzed in the report, is projected to record 25.7% CAGR and reach US$12 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy segment is readjusted to a revised 28.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $693.3 Million, While China is Forecast to Grow at 25.5% CAGR

The Urothelial Cancer Drugs market in the U.S. is estimated at US$693.3 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 25.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 23% and 21.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 17.6% CAGR.

Select Competitors (Total 42 Featured) -

AstraZeneca
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Co.
Exelixis, Inc
Genentech
GlaxoSmithKline
Merck
Novartis International AG
Pfizer

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Urothelial Cancer Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 2: World Historic Review for Urothelial Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 3: World 16-Year Perspective for Urothelial Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 5: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 6: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 8: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 9: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 10: World Urothelial Cancer Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- TABLE 11: USA Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 12: USA Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 13: USA 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
CANADA
- TABLE 14: Canada Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 15: Canada Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 16: Canada 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
JAPAN
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- TABLE 17: Japan Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 18: Japan Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 19: Japan 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
CHINA
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 21: China Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 22: China 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
EUROPE
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 23: Europe Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- TABLE 24: Europe Historic Review for Urothelial Cancer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 25: Europe 16-Year Perspective for Urothelial Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- TABLE 26: Europe Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
FRANCE
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- TABLE 29: France Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 30: France Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 31: France 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
GERMANY
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- TABLE 32: Germany Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 33: Germany Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 34: Germany 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
ITALY
- TABLE 35: Italy Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 36: Italy Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 37: Italy 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- TABLE 38: UK Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 39: UK Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 40: UK 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
REST OF EUROPE
- TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 42: Rest of Europe Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 43: Rest of Europe 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Urothelial Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 45: Asia-Pacific Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 46: Asia-Pacific 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
REST OF WORLD
- TABLE 47: Rest of World Recent Past, Current & Future Analysis for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- TABLE 48: Rest of World Historic Review for Urothelial Cancer Drugs by Treatment Class - Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- TABLE 49: Rest of World 16-Year Perspective for Urothelial Cancer Drugs by Treatment Class - Percentage Breakdown of Value Sales for Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030